16 IPOs went public in another active week for the IPO market, led by digital physicians network Doximity (DOCS), which soared 104% in its debut. The week’s IPOs were joined by four SPACs, as well as one postponement, Chinese social...read more
Acurx Pharmaceuticals, a phase 2 biotech developing antibiotics for antibiotic-resistant pathogens, raised $15 million by offering 2.5 million shares at $6, within the range of $5 to $7. At pricing, the company commands a fully diluted market value of $62...read more
Updated Monday, 6/21/21. 17 IPOs are scheduled to raise $6.3 billion in the week ahead, led by two billion-dollar deals. Chinese freight platform Full Truck Alliance (YMM) plans to raise $1.5 billion at a $19.7 billion market cap....read more
Acurx Pharmaceuticals, a Phase 2 biotech developing antibiotics for antibiotic-resistant pathogens, filed on Thursday with the SEC to raise up to $15 million in an initial public offering.
The company plans to raise $15 million by offering 2.5 million...read more
US IPO Weekly Recap: Doximity pops more than 100% in a 16 IPO week
16 IPOs went public in another active week for the IPO market, led by digital physicians network Doximity (DOCS), which soared 104% in its debut. The week’s IPOs were joined by four SPACs, as well as one postponement, Chinese social...read more
Micro-cap antibiotic biotech Acurx Pharmaceuticals prices IPO at $6 midpoint
Acurx Pharmaceuticals, a phase 2 biotech developing antibiotics for antibiotic-resistant pathogens, raised $15 million by offering 2.5 million shares at $6, within the range of $5 to $7. At pricing, the company commands a fully diluted market value of $62...read more
US IPO Week Ahead: Billion-dollar deals come to market in a 17 IPO week
Updated Monday, 6/21/21. 17 IPOs are scheduled to raise $6.3 billion in the week ahead, led by two billion-dollar deals. Chinese freight platform Full Truck Alliance (YMM) plans to raise $1.5 billion at a $19.7 billion market cap....read more
Micro-cap antibiotic biotech Acurx Pharmaceuticals files and sets terms for a $15 million IPO
Acurx Pharmaceuticals, a Phase 2 biotech developing antibiotics for antibiotic-resistant pathogens, filed on Thursday with the SEC to raise up to $15 million in an initial public offering. The company plans to raise $15 million by offering 2.5 million...read more